Trial reportArteriosclerosis, thrombosis, and vascular biology2017
Ezetimibe Increases Endogenous Cholesterol Excretion in Humans.
Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01603758. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Who cites it
10 citing papers in PubMed, 34 citations in OpenAlex.
- Hypocholesterolemic agents and the gut microbiota: a review of interactions and modulatory activity.Pharmacological reports : PR · 2026Review
- High cholesterol absorption efficiency interferes with bile acid metabolism and cholesterol elimination from the body.Journal of internal medicine · 2026Article
- Review
- Endothelium-Derived Relaxing Factors and Endothelial Function: A Systematic Review.Biomedicines · 2022Review
- FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice.Lipids in health and disease · 2022Article
- Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal transduction and targeted therapy · 2022Review
- Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters.Lipids in health and disease · 2020Article
- Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice.Journal of lipid research · 2019Article
- Review
- Endogenous Cholesterol Excretion Is Negatively Associated With Carotid Intima-Media Thickness in Humans.Arteriosclerosis, thrombosis, and vascular biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveEzetimibe improves cardiovascular outcomes when added to optimum statin treatment. It lowers low-density lipoprotein cholesterol and percent intestinal cholesterol absorption, but the exact cardioprotective mechanism is unknown. We tested the hypothesis that the dominant effect of ezetimibe is to increase the reverse transport of cholesterol from rapidly mixing endogenous cholesterol pool into the stool. APPROACH AND
resultsIn a randomized, placebo-controlled, double-blind parallel trial in 24 healthy subjects with low-density lipoprotein cholesterol 100 to 200 mg/dL, we measured cholesterol metabolism before and after a 6-week treatment period with ezetimibe 10 mg/d or placebo. Plasma cholesterol was labeled by intravenous infusion of cholesterol-d
conclusionsEzetimibe increased the efficiency of reverse cholesterol transport from rapidly mixing plasma and tissue pools into the stool. Further work is needed to examine the potential relation of reverse cholesterol transport and whole body cholesterol metabolism to coronary events and the treatment of atherosclerosis. CLINICAL TRIALS REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01603758.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.